Increasing Access to ZYMFENTRA through Strategic Partnerships
Celltrion USA is thrilled to announce a significant expansion in the accessibility of ZYMFENTRA (infliximab-dyyb), the premier FDA-approved subcutaneous infliximab. This progress is achieved through vital partnerships with some of the country's leading Pharmacy Benefit Managers (PBMs).
Enhancing Patient Options and Affordability
The growing presence of ZYMFENTRA across the U.S. market aims to provide patients with improved options and enhance their healthcare experience while also promoting affordability. The strategic collaborations not only empower patients but also support healthcare systems by providing innovative solutions and therapies.
Celltrion's Commitment to Innovation
Through diligent efforts, Celltrion has made strides in making ZYMFENTRA widely available, addressing the unmet needs of countless patients, healthcare providers, and payers alike. This success highlights Celltrion USA's profound commitment to delivering high-quality biologics and maintaining a robust supply chain.
Testimony from Leadership
According to Thomas Nusbickel, Chief Commercial Officer (CCO) at Celltrion USA, "Our extensive engagement has led to rapid expanded access for ZYMFENTRA. We are excited about its innovative therapeutic advantages and are committed to reaching as many patients as possible in the U.S." This statement underscores the company's dedication to improving patient outcomes through accessible treatment options.
Overview of ZYMFENTRA
ZYMFENTRA (infliximab-dyyb) has recently gained FDA approval, establishing its place as the sole subcutaneous infliximab for treating moderately to severely active ulcerative colitis and Crohn's disease. The approval was secured under the Biologics License Application (BLA), reflecting the rigorous standards set by health authorities.
Celltrion USA: A Leader in Biologics
Founded in 2018, Celltrion USA is dedicated to enhancing patients' lives by providing access to innovative biologics. With its headquarters in New Jersey, the company has successfully launched several biosimilars approved by the FDA, marking its commitment to excellence in medication development and healthcare delivery.
Understanding the Importance of ZYMFENTRA
ZYMFENTRA is designed for adults as a maintenance treatment option for ulcerative colitis and Crohn's disease following prior intravenous therapy with infliximab. It functions by inhibiting the effect of tumor necrosis factor-alpha (TNF-alpha), which plays a significant role in inflammatory processes.
Given its subcutaneous administration, ZYMFENTRA provides a more convenient option compared to traditional intravenous therapies, aligning with modern healthcare's shift towards patient-friendly solutions.
Safety and Caution Information
As with any medication, ZYMFENTRA comes with specific safety considerations. Patients may experience serious infections, and the medication is contraindicated for individuals with a history of severe hypersensitivity reactions. Regular monitoring and consultations with healthcare providers are crucial to maximize the benefits while minimizing risks.
Conclusion
The expansion of ZYMFENTRA's accessibility represents a pivotal moment for patients suffering from chronic conditions across the U.S. By partnering with key PBMs, Celltrion USA is not just enhancing availability but is also focused on making treatment both effective and affordable. This initiative underscores the importance of innovative therapeutics in improving patient care and driving healthcare improvement nationwide.
Frequently Asked Questions
What is ZYMFENTRA?
ZYMFENTRA is a prescription medication used for the maintenance treatment of moderately to severely active ulcerative colitis and Crohn's disease in adults.
How does ZYMFENTRA work?
ZYMFENTRA blocks the action of TNF-alpha, a protein that contributes to inflammation in various diseases, helping to manage symptoms effectively.
What are the common side effects of ZYMFENTRA?
Common side effects include injection site reactions, upper respiratory infections, and headache. Monitoring for serious infections is also necessary.
Who should not use ZYMFENTRA?
Individuals with a known severe hypersensitivity to infliximab-dyyb or any of its components should avoid using ZYMFENTRA.
Where can I learn more about ZYMFENTRA?
For detailed information about ZYMFENTRA, including prescribing details, consult your healthcare provider or refer to Celltrion USA's resources.
